You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndacaterol
Accession NumberDB05039
TypeSmall Molecule
GroupsApproved
DescriptionIndacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Structure
Thumb
Synonyms
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one
QAB 149
QAB-149
QAB149
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arcapta Neohalercapsule75 ug/1oral; respiratory (inhalation)Novartis Pharmaceuticals Corporation2011-07-01Not applicableUs
Hirobriz BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez Breezhalercapsule75 mcginhalationNovartis Pharmaceuticals Canada Inc2012-03-05Not applicableCanada
Onbrez BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Onbrez BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule300 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerInhalation powder, hard capsule150 μgInhalation useNovartis Europharm Ltd.  2009-11-30Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Arcapta Novartis
HirobrizNot Available
OnbrezNovartis
Onbrize Not Available
Brand mixtures
NameLabellerIngredients
Ultibro BreezhalerNovartis Pharmaceuticals Canada Inc
Utibron NeohalerNovartis Pharmaceuticals Corporation
Salts
Name/CASStructureProperties
Indacaterol Maleate
753498-25-8
Thumb
  • InChI Key: IREJFXIHXRZFER-PCBAQXHCSA-N
  • Monoisotopic Mass: 508.220951388
  • Average Mass: 508.5629
DBSALT000101
Categories
UNII8OR09251MQ
CAS number312753-06-3
WeightAverage: 392.4907
Monoisotopic: 392.209992772
Chemical FormulaC24H28N2O3
InChI KeyInChIKey=QZZUEBNBZAPZLX-QFIPXVFZSA-N
InChI
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
IUPAC Name
5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one
SMILES
CCC1=C(CC)C=C2CC(CC2=C1)NC[[email protected]](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroxyquinolones. These are compounds containing a quinoline moiety bearing a hydroxyl group and a ketone. Quinoline or benzo[b]pyridine is a bicyclic compound that consists of benzene fused to a pyridine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinolones and derivatives
Direct ParentHydroxyquinolones
Alternative Parents
Substituents
  • Hydroxyquinolone
  • 8-hydroxyquinoline
  • Hydroxyquinoline
  • Dihydroquinolone
  • Dihydroquinoline
  • Indane
  • Aralkylamine
  • Pyridinone
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Secondary alcohol
  • Lactam
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
PharmacodynamicsBronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β(2) -agonists and anticholinergics, either alone or in combination. Currently available β(2) -agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-acting β(2) -agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Furthermore, this chiral compound it is given as the R-enantiomer and acts as a full agonist. Cough was the most commonly reported adverse effect with use of indacaterol. Compared to salmeterol, it has 35% more agonist activity. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. [PMID: 22499359]
Mechanism of actionIndacaterol works by stimulating adrenergic beta-2 receptors in the smooth muscle of the airways. This causes relaxation of the muscle, thereby increasing the diameter of the airways, which become constricted in asthma and COPD. It is also long acting due to its high affinity to the lipid raft domains in the airway membrane so it slowly dissociates from the receptors. Indacaterol also has a high intrinsic efficacy so it is also very rapid acting - onset of action occurs within 5 minutes. The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.
Related Articles
AbsorptionThe median time to reach peak serum concentrations of indacaterol was approximately 15 minutes after single or repeated inhaled doses. Absolute bioavailability of indacaterol after an inhaled dose was on average 43-45%.
Volume of distribution

After intravenous infusion the volume of distribution (Vz) of indacaterol was 2,361 L to 2,557 L indicating an extensive distribution.

Protein bindingThe in vitro human serum and plasma protein binding was 94.1-95.3% and 95.1-96.2%, respectively.
Metabolism

After oral administration of radiolabeled indacaterol, unchanged indacaterol was the main component in serum, accounting for about one third of total drug-related AUC over 24 hours. The monohydroxylated derivative, glucuronide conjugate, and the 8-O-glucuronide were the most prominent metabolites in serum. Other metabolites identified include a diastereomer of the hydroxylated derivative, a N-glucuronide of indacaterol, and C- and N-dealkylated products. In vitro investigations indicated that UGT1A1 was the only UGT isoform that metabolized indacaterol to the phenolic O-glucuronide. CYP3A4 is the predominant isoenzyme responsible for hydroxylation of indacaterol.

SubstrateEnzymesProduct
Indacaterol
Not Available
8-O-glucuronideDetails
Route of eliminationRenal clearance plays a minor role (about 2 to 6% of systemic clearance) in the elimination of systemically available indacaterol. In a human ADME study where indacaterol was given orally, the fecal route of excretion was dominant over the urinary route. Indacaterol was excreted into human feces primarily as unchanged parent drug (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose).
Half lifeIndacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.
Clearance

Renal clearance of indacaterol is, on average, between 0.46 and 1.2 L/h. Serum clearance of indacaterol is 18.8 L/h to 23.3 L/h.

ToxicityThe expected signs and symptoms associated with overdosage of indacaterol are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of indacaterol.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.5
Caco-2 permeable-0.6288
P-glycoprotein substrateSubstrate0.6953
P-glycoprotein inhibitor INon-inhibitor0.9284
P-glycoprotein inhibitor IINon-inhibitor0.9178
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.8148
CYP450 2D6 substrateNon-substrate0.6907
CYP450 3A4 substrateSubstrate0.5896
CYP450 1A2 substrateInhibitor0.553
CYP450 2C9 inhibitorNon-inhibitor0.56
CYP450 2D6 inhibitorNon-inhibitor0.8547
CYP450 2C19 inhibitorNon-inhibitor0.5581
CYP450 3A4 inhibitorNon-inhibitor0.6546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5888
Ames testNon AMES toxic0.7577
CarcinogenicityNon-carcinogens0.8559
BiodegradationNot ready biodegradable0.9856
Rat acute toxicity2.6531 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9657
hERG inhibition (predictor II)Inhibitor0.6406
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral; respiratory (inhalation)75 ug/1
Capsuleinhalation75 mcg
Inhalation powder, hard capsuleInhalation use150 μg
Inhalation powder, hard capsuleInhalation use300 μg
Kit; capsuleinhalation
Capsulerespiratory (inhalation)
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6521260 No1996-01-312016-01-31Us
US6582678 No1998-04-242018-04-24Us
US6878721 No2000-10-102020-10-10Us
US7229607 No2001-04-092021-04-09Us
US7736670 No2001-06-272021-06-27Us
US7820694 No2000-06-022020-06-02Us
US8029768 No2001-04-092021-04-09Us
US8048451 No2001-06-272021-06-27Us
US8067437 No2000-06-022020-06-02Us
US8182838 No2008-10-202028-10-20Us
US8283362 No2000-06-022020-06-02Us
US8303991 No2001-06-272021-06-27Us
US8435567 No2001-06-272021-06-27Us
US8479730 No2008-10-112028-10-11Us
US8580306 No2001-06-272021-06-27Us
US8658673 No2000-06-022020-06-02Us
US8796307 No2000-06-022020-06-02Us
US8956661 No2001-06-272021-06-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195-202°C with decompositionNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00798 mg/mLALOGPS
logP3.31ALOGPS
logP3.26ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)8.51ChemAxon
pKa (Strongest Basic)9.71ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.59 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity118.1 m3·mol-1ChemAxon
Polarizability44.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007 Mar;29(3):575-81. Epub 2006 Nov 29. [PubMed:17135231 ]
  2. Kagan M, Dain J, Peng L, Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. 2012 Sep;40(9):1712-22. doi: 10.1124/dmd.112.046151. Epub 2012 May 30. [PubMed:22648561 ]
  3. Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. [PubMed:23641160 ]
External Links
ATC CodesR03AL04R03AC18
AHFS Codes
  • 12:12.08.12
PDB EntriesNot Available
FDA labelDownload (360 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneIndacaterol may increase the hypokalemic activities of 4-Androstenedione.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Indacaterol.
AcebutololAcebutolol may decrease the bronchodilatory activities of Indacaterol.
AcetaminophenThe serum concentration of Indacaterol can be increased when it is combined with Acetaminophen.
AfatinibThe serum concentration of Indacaterol can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Indacaterol can be increased when it is combined with Albendazole.
AlclometasoneIndacaterol may increase the hypokalemic activities of Alclometasone.
AldosteroneIndacaterol may increase the hypokalemic activities of Aldosterone.
AldosteroneThe serum concentration of Indacaterol can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Indacaterol can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Indacaterol can be increased when it is combined with Alfentanil.
AlprenololAlprenolol may decrease the bronchodilatory activities of Indacaterol.
AmantadineThe serum concentration of Indacaterol can be increased when it is combined with Amantadine.
AmcinonideIndacaterol may increase the hypokalemic activities of Amcinonide.
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.
Aminohippuric acidThe serum concentration of Indacaterol can be increased when it is combined with Aminohippuric acid.
AminophyllineThe risk or severity of adverse effects can be increased when Aminophylline is combined with Indacaterol.
AmiodaroneThe serum concentration of Indacaterol can be decreased when it is combined with Amiodarone.
AmiodaroneIndacaterol may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indacaterol.
AmlodipineThe serum concentration of Indacaterol can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Indacaterol can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Indacaterol can be increased when it is combined with Amsacrine.
AnagrelideIndacaterol may increase the QTc-prolonging activities of Anagrelide.
AprepitantThe serum concentration of Indacaterol can be increased when it is combined with Aprepitant.
Arsenic trioxideIndacaterol may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherIndacaterol may increase the QTc-prolonging activities of Artemether.
AsenapineIndacaterol may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Indacaterol can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Indacaterol can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Indacaterol can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the tachycardic activities of Indacaterol.
AtorvastatinThe serum concentration of Indacaterol can be increased when it is combined with Atorvastatin.
AtosibanThe risk or severity of adverse effects can be increased when Indacaterol is combined with Atosiban.
AzelastineThe serum concentration of Indacaterol can be increased when it is combined with Azelastine.
AzithromycinIndacaterol may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Indacaterol can be increased when it is combined with Azithromycin.
Beclomethasone dipropionateIndacaterol may increase the hypokalemic activities of Beclomethasone dipropionate.
BedaquilineIndacaterol may increase the QTc-prolonging activities of Bedaquiline.
BendroflumethiazideIndacaterol may increase the hypokalemic activities of Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Indacaterol.
BenzocaineThe serum concentration of Indacaterol can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Indacaterol can be increased when it is combined with Bepridil.
BetahistineThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Betahistine.
BetamethasoneIndacaterol may increase the hypokalemic activities of Betamethasone.
BetaxololBetaxolol may decrease the bronchodilatory activities of Indacaterol.
BexaroteneThe serum concentration of Indacaterol can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Indacaterol can be increased when it is combined with Biperiden.
BisoprololBisoprolol may decrease the bronchodilatory activities of Indacaterol.
BoceprevirThe metabolism of Indacaterol can be decreased when combined with Boceprevir.
BopindololBopindolol may decrease the bronchodilatory activities of Indacaterol.
BortezomibThe metabolism of Indacaterol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Indacaterol can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Indacaterol can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Indacaterol can be increased when it is combined with Bromocriptine.
BudesonideIndacaterol may increase the hypokalemic activities of Budesonide.
BumetanideIndacaterol may increase the hypokalemic activities of Bumetanide.
BupranololBupranolol may decrease the bronchodilatory activities of Indacaterol.
BuprenorphineThe serum concentration of Indacaterol can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Indacaterol can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Indacaterol can be increased when it is combined with Cabazitaxel.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Indacaterol.
CanagliflozinThe serum concentration of Indacaterol can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Indacaterol can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Indacaterol can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Indacaterol can be decreased when it is combined with Carbamazepine.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Indacaterol.
CarteololCarteolol may decrease the bronchodilatory activities of Indacaterol.
CarvedilolThe serum concentration of Indacaterol can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Indacaterol can be increased when it is combined with Caspofungin.
CeliprololCeliprolol may decrease the bronchodilatory activities of Indacaterol.
CeritinibThe serum concentration of Indacaterol can be increased when it is combined with Ceritinib.
CeritinibIndacaterol may increase the QTc-prolonging activities of Ceritinib.
ChloroquineIndacaterol may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Indacaterol can be increased when it is combined with Chloroquine.
ChlorothiazideIndacaterol may increase the hypokalemic activities of Chlorothiazide.
ChlorpromazineIndacaterol may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Indacaterol can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Indacaterol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Indacaterol can be increased when it is combined with Chlorprothixene.
ChlorthalidoneIndacaterol may increase the hypokalemic activities of Chlorthalidone.
CholesterolThe serum concentration of Indacaterol can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Indacaterol can be decreased when it is combined with Cholic Acid.
CiclesonideIndacaterol may increase the hypokalemic activities of Ciclesonide.
CilazaprilThe serum concentration of Indacaterol can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Indacaterol can be decreased when it is combined with Cimetidine.
CiprofloxacinIndacaterol may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Indacaterol can be increased when it is combined with Ciprofloxacin.
CisaprideIndacaterol may increase the QTc-prolonging activities of Cisapride.
CitalopramThe serum concentration of Indacaterol can be increased when it is combined with Citalopram.
CitalopramIndacaterol may increase the QTc-prolonging activities of Citalopram.
ClarithromycinIndacaterol may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Indacaterol can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Indacaterol can be decreased when combined with Clemastine.
Clobetasol propionateIndacaterol may increase the hypokalemic activities of Clobetasol propionate.
ClocortoloneIndacaterol may increase the hypokalemic activities of Clocortolone.
ClofazimineThe serum concentration of Indacaterol can be increased when it is combined with Clofazimine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indacaterol.
ClotrimazoleThe metabolism of Indacaterol can be decreased when combined with Clotrimazole.
ClozapineIndacaterol may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Indacaterol can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Indacaterol can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Indacaterol can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Indacaterol can be increased when it is combined with Conivaptan.
Cortisone acetateIndacaterol may increase the hypokalemic activities of Cortisone acetate.
CrizotinibIndacaterol may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Indacaterol can be decreased when combined with Crizotinib.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.
CyclophosphamideThe serum concentration of Indacaterol can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Indacaterol can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Indacaterol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Indacaterol can be increased when it is combined with Dactinomycin.
DarunavirThe metabolism of Indacaterol can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Indacaterol can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Indacaterol can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Indacaterol can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneIndacaterol may increase the hypokalemic activities of Dehydroepiandrosterone.
dehydroepiandrosterone sulfateIndacaterol may increase the hypokalemic activities of dehydroepiandrosterone sulfate.
DelavirdineThe metabolism of Indacaterol can be decreased when combined with Delavirdine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.
DesloratadineThe serum concentration of Indacaterol can be increased when it is combined with Desloratadine.
DesoximetasoneIndacaterol may increase the hypokalemic activities of Desoximetasone.
Desoxycorticosterone acetateIndacaterol may increase the hypokalemic activities of Desoxycorticosterone acetate.
DexamethasoneIndacaterol may increase the hypokalemic activities of Dexamethasone.
DexamethasoneThe serum concentration of Indacaterol can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateIndacaterol may increase the hypokalemic activities of Dexamethasone isonicotinate.
DextromethorphanThe serum concentration of Indacaterol can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Indacaterol can be increased when it is combined with Diclofenac.
DiflorasoneIndacaterol may increase the hypokalemic activities of Diflorasone.
DifluocortoloneIndacaterol may increase the hypokalemic activities of Difluocortolone.
DifluprednateIndacaterol may increase the hypokalemic activities of Difluprednate.
DigoxinThe serum concentration of Indacaterol can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Indacaterol can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Indacaterol can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Indacaterol can be increased when it is combined with Dipyridamole.
DisopyramideIndacaterol may increase the QTc-prolonging activities of Disopyramide.
DofetilideIndacaterol may increase the QTc-prolonging activities of Dofetilide.
DolasetronIndacaterol may increase the QTc-prolonging activities of Dolasetron.
DomperidoneIndacaterol may increase the QTc-prolonging activities of Domperidone.
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Indacaterol.
DoxazosinThe serum concentration of Indacaterol can be increased when it is combined with Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Indacaterol.
DoxorubicinThe serum concentration of Indacaterol can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Indacaterol can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Indacaterol can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Indacaterol can be decreased when combined with Dronedarone.
DronedaroneIndacaterol may increase the QTc-prolonging activities of Dronedarone.
DroperidolIndacaterol may increase the QTc-prolonging activities of Droperidol.
DyphyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Indacaterol.
EfavirenzThe serum concentration of Indacaterol can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Indacaterol can be increased when it is combined with Elbasvir.
EliglustatIndacaterol may increase the QTc-prolonging activities of Eliglustat.
EnalaprilThe serum concentration of Indacaterol can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Indacaterol can be increased when it is combined with Enzalutamide.
EquileninIndacaterol may increase the hypokalemic activities of Equilenin.
EquilinIndacaterol may increase the hypokalemic activities of Equilin.
ErgonovineThe serum concentration of Indacaterol can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Indacaterol can be increased when it is combined with Ergotamine.
ErythromycinIndacaterol may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Indacaterol can be decreased when combined with Erythromycin.
EscitalopramIndacaterol may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Indacaterol can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Indacaterol.
EsmololEsmolol may decrease the bronchodilatory activities of Indacaterol.
EstramustineThe serum concentration of Indacaterol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Indacaterol can be decreased when it is combined with Estriol.
EstroneIndacaterol may increase the hypokalemic activities of Estrone.
EstroneThe serum concentration of Indacaterol can be decreased when it is combined with Estrone.
Etacrynic acidIndacaterol may increase the hypokalemic activities of Etacrynic acid.
EtoposideThe serum concentration of Indacaterol can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Indacaterol can be decreased when it is combined with Etravirine.
FelodipineThe serum concentration of Indacaterol can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Indacaterol can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Indacaterol can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Indacaterol can be increased when it is combined with Fidaxomicin.
FlecainideIndacaterol may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Indacaterol can be decreased when combined with Fluconazole.
FludrocortisoneIndacaterol may increase the hypokalemic activities of Fludrocortisone.
FlumethasoneIndacaterol may increase the hypokalemic activities of Flumethasone.
FlunisolideIndacaterol may increase the hypokalemic activities of Flunisolide.
Fluocinolone AcetonideIndacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.
FluocinonideIndacaterol may increase the hypokalemic activities of Fluocinonide.
FluocortoloneIndacaterol may increase the hypokalemic activities of Fluocortolone.
FluorometholoneIndacaterol may increase the hypokalemic activities of Fluorometholone.
FluoxetineThe serum concentration of Indacaterol can be increased when it is combined with Fluoxetine.
FluoxetineIndacaterol may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolThe serum concentration of Indacaterol can be increased when it is combined with Flupentixol.
FlupentixolIndacaterol may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Indacaterol can be increased when it is combined with Fluphenazine.
FluprednideneIndacaterol may increase the hypokalemic activities of Fluprednidene.
FluprednisoloneIndacaterol may increase the hypokalemic activities of Fluprednisolone.
FlurandrenolideIndacaterol may increase the hypokalemic activities of Flurandrenolide.
FlurazepamThe serum concentration of Indacaterol can be increased when it is combined with Flurazepam.
Fluticasone furoateIndacaterol may increase the hypokalemic activities of Fluticasone furoate.
Fluticasone PropionateIndacaterol may increase the hypokalemic activities of Fluticasone Propionate.
FluvoxamineThe metabolism of Indacaterol can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Indacaterol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Indacaterol can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Indacaterol can be increased when combined with Fosphenytoin.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.
FurosemideIndacaterol may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Indacaterol can be increased when it is combined with Fusidic Acid.
Gadobenic acidIndacaterol may increase the QTc-prolonging activities of Gadobenic acid.
GefitinibThe serum concentration of Indacaterol can be increased when it is combined with Gefitinib.
GemifloxacinIndacaterol may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Indacaterol can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Indacaterol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Indacaterol can be increased when it is combined with Glycerol.
GoserelinIndacaterol may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Indacaterol can be increased when it is combined with Gramicidin D.
GranisetronIndacaterol may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe serum concentration of Indacaterol can be increased when it is combined with Grepafloxacin.
HaloperidolIndacaterol may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Indacaterol can be increased when it is combined with Haloperidol.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Indacaterol.
HydrochlorothiazideIndacaterol may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocortisoneIndacaterol may increase the hypokalemic activities of Hydrocortisone.
HydrocortisoneThe serum concentration of Indacaterol can be increased when it is combined with Hydrocortisone.
HydroflumethiazideIndacaterol may increase the hypokalemic activities of Hydroflumethiazide.
IbutilideIndacaterol may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Indacaterol can be increased when it is combined with Idelalisib.
IloperidoneIndacaterol may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Indacaterol can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indacaterol.
IndapamideIndacaterol may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Indacaterol can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indacaterol can be increased when it is combined with Indomethacin.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Indacaterol.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.
IsavuconazoniumThe metabolism of Indacaterol can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.
IsradipineThe metabolism of Indacaterol can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Indacaterol can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Indacaterol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Indacaterol can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Indacaterol can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Indacaterol can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Indacaterol can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Indacaterol can be increased when it is combined with Lapatinib.
LenvatinibIndacaterol may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideIndacaterol may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinIndacaterol may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Indacaterol can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Indacaterol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Indacaterol can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Indacaterol can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Indacaterol can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Indacaterol can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Indacaterol can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Indacaterol can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Indacaterol can be increased when it is combined with Lopinavir.
LopinavirIndacaterol may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Indacaterol can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Indacaterol can be increased when it is combined with Losartan.
LovastatinThe metabolism of Indacaterol can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Indacaterol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Indacaterol can be decreased when it is combined with Lumacaftor.
LumefantrineIndacaterol may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineThe serum concentration of Indacaterol can be increased when it is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Indacaterol.
MebendazoleThe serum concentration of Indacaterol can be increased when it is combined with Mebendazole.
MedrysoneIndacaterol may increase the hypokalemic activities of Medrysone.
MefloquineThe serum concentration of Indacaterol can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Indacaterol can be increased when it is combined with Megestrol acetate.
MelengestrolIndacaterol may increase the hypokalemic activities of Melengestrol.
MeprobamateThe serum concentration of Indacaterol can be increased when it is combined with Meprobamate.
MethadoneIndacaterol may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Indacaterol can be increased when it is combined with Methadone.
MethyclothiazideIndacaterol may increase the hypokalemic activities of Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Indacaterol.
MethylprednisoloneIndacaterol may increase the hypokalemic activities of Methylprednisolone.
MetolazoneIndacaterol may increase the hypokalemic activities of Metolazone.
MetoprololThe serum concentration of Indacaterol can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Indacaterol can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Indacaterol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Indacaterol can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Indacaterol can be decreased when combined with Mifepristone.
MifepristoneIndacaterol may increase the QTc-prolonging activities of Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Indacaterol.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indacaterol.
MitomycinThe serum concentration of Indacaterol can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Indacaterol can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Indacaterol can be decreased when it is combined with Mitoxantrone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Indacaterol.
ModafinilThe serum concentration of Indacaterol can be decreased when it is combined with Modafinil.
MometasoneIndacaterol may increase the hypokalemic activities of Mometasone.
MorphineThe serum concentration of Indacaterol can be increased when it is combined with Morphine.
MoxifloxacinIndacaterol may increase the QTc-prolonging activities of Moxifloxacin.
NadololNadolol may decrease the bronchodilatory activities of Indacaterol.
NafcillinThe serum concentration of Indacaterol can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Indacaterol can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Indacaterol can be increased when it is combined with Naringenin.
NebivololNebivolol may decrease the bronchodilatory activities of Indacaterol.
NefazodoneThe serum concentration of Indacaterol can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Indacaterol can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Indacaterol can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Indacaterol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Indacaterol can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Indacaterol.
NicardipineThe serum concentration of Indacaterol can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Indacaterol can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Indacaterol can be decreased when combined with Nilotinib.
NilotinibIndacaterol may increase the QTc-prolonging activities of Nilotinib.
NisoldipineThe serum concentration of Indacaterol can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Indacaterol can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Indacaterol can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Indacaterol can be decreased when it is combined with Norethisterone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indacaterol.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Indacaterol.
OfloxacinIndacaterol may increase the QTc-prolonging activities of Ofloxacin.
OlaparibThe metabolism of Indacaterol can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Indacaterol can be increased when it is combined with Omeprazole.
OndansetronIndacaterol may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Indacaterol can be increased when it is combined with Osimertinib.
OxprenololOxprenolol may decrease the bronchodilatory activities of Indacaterol.
P-NitrophenolThe serum concentration of Indacaterol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Indacaterol can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Indacaterol can be increased when it is combined with Palbociclib.
PaliperidoneIndacaterol may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Indacaterol can be increased when it is combined with Palmitic Acid.
PanobinostatIndacaterol may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Indacaterol can be increased when it is combined with Pantoprazole.
ParamethasoneIndacaterol may increase the hypokalemic activities of Paramethasone.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.
ParoxetineThe serum concentration of Indacaterol can be increased when it is combined with Paroxetine.
PazopanibIndacaterol may increase the QTc-prolonging activities of Pazopanib.
PenbutololPenbutolol may decrease the bronchodilatory activities of Indacaterol.
PentamidineIndacaterol may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Indacaterol can be increased when combined with Pentobarbital.
PerflutrenIndacaterol may increase the QTc-prolonging activities of Perflutren.
PerindoprilThe serum concentration of Indacaterol can be increased when it is combined with Perindopril.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Indacaterol.
PhenobarbitalThe serum concentration of Indacaterol can be decreased when it is combined with Phenobarbital.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Indacaterol.
PhenytoinThe metabolism of Indacaterol can be increased when combined with Phenytoin.
PimozideThe serum concentration of Indacaterol can be increased when it is combined with Pimozide.
PimozideIndacaterol may increase the QTc-prolonging activities of Pimozide.
PindololPindolol may decrease the bronchodilatory activities of Indacaterol.
PiretanideIndacaterol may increase the hypokalemic activities of Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Indacaterol.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Indacaterol.
Platelet Activating FactorThe serum concentration of Indacaterol can be decreased when it is combined with Platelet Activating Factor.
PolythiazideIndacaterol may increase the hypokalemic activities of Polythiazide.
PonatinibThe serum concentration of Indacaterol can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Indacaterol can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Indacaterol can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Indacaterol can be increased when it is combined with Prazosin.
PrednicarbateIndacaterol may increase the hypokalemic activities of Prednicarbate.
PrednisoloneIndacaterol may increase the hypokalemic activities of Prednisolone.
PrednisoneIndacaterol may increase the hypokalemic activities of Prednisone.
PrednisoneThe serum concentration of Indacaterol can be increased when it is combined with Prednisone.
PregnenoloneIndacaterol may increase the hypokalemic activities of Pregnenolone.
PrimaquineIndacaterol may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Indacaterol can be increased when combined with Primidone.
ProbenecidThe serum concentration of Indacaterol can be increased when it is combined with Probenecid.
ProcainamideIndacaterol may increase the QTc-prolonging activities of Procainamide.
ProgesteroneThe serum concentration of Indacaterol can be decreased when it is combined with Progesterone.
PromazineIndacaterol may increase the QTc-prolonging activities of Promazine.
PromethazineThe serum concentration of Indacaterol can be increased when it is combined with Promethazine.
PropafenoneIndacaterol may increase the QTc-prolonging activities of Propafenone.
PropafenoneThe serum concentration of Indacaterol can be increased when it is combined with Propafenone.
PropranololPropranolol may decrease the bronchodilatory activities of Indacaterol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indacaterol.
QuercetinThe serum concentration of Indacaterol can be increased when it is combined with Quercetin.
QuetiapineIndacaterol may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Indacaterol can be increased when it is combined with Quinacrine.
QuinethazoneIndacaterol may increase the hypokalemic activities of Quinethazone.
QuinidineThe serum concentration of Indacaterol can be increased when it is combined with Quinidine.
QuinidineIndacaterol may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Indacaterol can be increased when it is combined with Quinine.
QuinineIndacaterol may increase the QTc-prolonging activities of Quinine.
RanitidineThe serum concentration of Indacaterol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Indacaterol can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.
ReboxetineThe serum concentration of Indacaterol can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Indacaterol can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Indacaterol can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Indacaterol can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Indacaterol can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Indacaterol can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Indacaterol can be increased when it is combined with Rilpivirine.
RimexoloneIndacaterol may increase the hypokalemic activities of Rimexolone.
RitonavirThe serum concentration of Indacaterol can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Indacaterol can be increased when it is combined with Rolapitant.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Indacaterol.
SaquinavirIndacaterol may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Indacaterol can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Indacaterol can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Indacaterol can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Indacaterol can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Indacaterol can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Indacaterol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Indacaterol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Indacaterol can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Indacaterol can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Indacaterol can be increased when it is combined with Sorafenib.
SotalolSotalol may decrease the bronchodilatory activities of Indacaterol.
SotalolIndacaterol may increase the QTc-prolonging activities of Sotalol.
SpironolactoneThe serum concentration of Indacaterol can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Indacaterol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Indacaterol can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Indacaterol can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Indacaterol can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Indacaterol can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleIndacaterol may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Indacaterol can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Indacaterol can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Indacaterol can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Indacaterol can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Indacaterol can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Indacaterol can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Indacaterol can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Indacaterol can be decreased when combined with Telaprevir.
TelavancinIndacaterol may increase the QTc-prolonging activities of Telavancin.
TelithromycinIndacaterol may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Indacaterol can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Indacaterol can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Indacaterol can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Indacaterol can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Indacaterol can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Indacaterol can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Indacaterol can be increased when it is combined with Testosterone.
TetrabenazineIndacaterol may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.
ThioridazineIndacaterol may increase the QTc-prolonging activities of Thioridazine.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Indacaterol.
TicagrelorThe serum concentration of Indacaterol can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Indacaterol can be decreased when combined with Ticlopidine.
TimololTimolol may decrease the bronchodilatory activities of Indacaterol.
TixocortolIndacaterol may increase the hypokalemic activities of Tixocortol.
TocilizumabThe serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Indacaterol.
TolvaptanThe serum concentration of Indacaterol can be increased when it is combined with Tolvaptan.
TorasemideIndacaterol may increase the hypokalemic activities of Torasemide.
ToremifeneIndacaterol may increase the QTc-prolonging activities of Toremifene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indacaterol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.
TrazodoneThe serum concentration of Indacaterol can be decreased when it is combined with Trazodone.
TriamcinoloneIndacaterol may increase the hypokalemic activities of Triamcinolone.
TrichlormethiazideIndacaterol may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Indacaterol can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Indacaterol can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Indacaterol can be decreased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indacaterol.
TroleandomycinThe serum concentration of Indacaterol can be increased when it is combined with Troleandomycin.
VandetanibIndacaterol may increase the QTc-prolonging activities of Vandetanib.
VemurafenibIndacaterol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Indacaterol can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Indacaterol can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Indacaterol can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Indacaterol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Indacaterol can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Indacaterol can be decreased when combined with Voriconazole.
ZimelidineThe serum concentration of Indacaterol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Indacaterol can be decreased when combined with Ziprasidone.
ZiprasidoneIndacaterol may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolIndacaterol may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Cazzola M, Matera MG, Lotvall J: Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. [PubMed:16022567 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on September 27, 2016 02:27